Aurobindo Pharma Ltd
NSE:AUROPHARMA
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Price:
1 262.45
INR
0.65%
Market Closed
Market Cap:
733.2B
INR
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
AUROPHARMA Alert
Aurobindo Pharma Ltd
1262.45
+8.10 (+0.65%)
| 52 Week Range |
989.8
1 568.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Aurobindo Pharma Ltd
Income Statement
Earnings Waterfall
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
|
Revenue
|
297.2B
INR
|
|
Cost of Revenue
|
-125.2B
INR
|
|
Gross Profit
|
172B
INR
|
|
Operating Expenses
|
-124.9B
INR
|
|
Operating Income
|
47.1B
INR
|
|
Other Expenses
|
-11.9B
INR
|
|
Net Income
|
35.2B
INR
|
Income Statement
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
Currency: INR
| Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||||||
| Revenue |
92 954
N/A
|
102 627
+10%
|
112 883
+10%
|
121 205
+7%
|
125 481
+4%
|
130 320
+4%
|
133 714
+3%
|
139 552
+4%
|
143 832
+3%
|
147 936
+3%
|
151 942
+3%
|
150 899
-1%
|
150 021
-1%
|
156 625
+4%
|
160 924
+3%
|
164 998
+3%
|
170 714
+3%
|
173 869
+2%
|
183 205
+5%
|
195 636
+7%
|
207 579
+6%
|
216 070
+4%
|
222 323
+3%
|
230 985
+4%
|
235 787
+2%
|
244 616
+4%
|
249 315
+2%
|
247 746
-1%
|
245 518
-1%
|
240 103
-2%
|
236 476
-2%
|
234 555
-1%
|
239 894
+2%
|
237 869
-1%
|
241 918
+2%
|
248 554
+3%
|
254 700
+2%
|
269 500
+6%
|
278 947
+4%
|
290 019
+4%
|
297 184
+2%
|
|
| Gross Profit | ||||||||||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(40 953)
|
(44 408)
|
(50 298)
|
(61 174)
|
(56 251)
|
(58 725)
|
(59 366)
|
(69 656)
|
(63 665)
|
(64 392)
|
(65 981)
|
(72 844)
|
(62 951)
|
(64 782)
|
(65 860)
|
(74 325)
|
(71 622)
|
(74 372)
|
(80 096)
|
(95 495)
|
(91 039)
|
(94 293)
|
(96 044)
|
(106 119)
|
(98 441)
|
(99 915)
|
(99 988)
|
(108 053)
|
(98 613)
|
(98 512)
|
(100 231)
|
(110 535)
|
(106 607)
|
(107 231)
|
(108 865)
|
(123 259)
|
(115 613)
|
(122 300)
|
(124 730)
|
(136 602)
|
(125 209)
|
|
| Gross Profit |
51 999
N/A
|
58 217
+12%
|
62 584
+8%
|
60 031
-4%
|
69 229
+15%
|
71 594
+3%
|
74 347
+4%
|
69 896
-6%
|
80 167
+15%
|
83 544
+4%
|
85 961
+3%
|
78 055
-9%
|
87 069
+12%
|
91 842
+5%
|
95 063
+4%
|
90 673
-5%
|
99 092
+9%
|
99 497
+0%
|
103 109
+4%
|
100 140
-3%
|
116 540
+16%
|
121 777
+4%
|
126 279
+4%
|
124 866
-1%
|
137 347
+10%
|
144 702
+5%
|
149 328
+3%
|
139 693
-6%
|
146 905
+5%
|
141 591
-4%
|
136 245
-4%
|
124 020
-9%
|
133 287
+7%
|
130 637
-2%
|
133 053
+2%
|
125 295
-6%
|
139 087
+11%
|
147 201
+6%
|
154 217
+5%
|
153 417
-1%
|
171 975
+12%
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(30 473)
|
(34 836)
|
(39 432)
|
(37 246)
|
(46 233)
|
(47 207)
|
(48 225)
|
(41 889)
|
(50 743)
|
(52 793)
|
(54 557)
|
(47 855)
|
(57 725)
|
(60 837)
|
(63 020)
|
(58 204)
|
(67 644)
|
(69 546)
|
(72 801)
|
(67 105)
|
(80 993)
|
(85 343)
|
(89 498)
|
(85 520)
|
(97 542)
|
(102 251)
|
(105 536)
|
(95 502)
|
(104 848)
|
(102 363)
|
(100 765)
|
(91 017)
|
(103 129)
|
(105 297)
|
(108 902)
|
(99 919)
|
(112 951)
|
(116 594)
|
(118 161)
|
(109 570)
|
(124 856)
|
|
| Selling, General & Administrative |
(9 156)
|
(10 566)
|
(11 331)
|
(32 592)
|
(12 770)
|
(13 130)
|
(14 247)
|
(36 662)
|
(16 135)
|
(16 671)
|
(17 111)
|
(41 860)
|
(18 259)
|
(19 180)
|
(20 131)
|
(49 987)
|
(22 368)
|
(23 436)
|
(24 527)
|
(56 284)
|
(27 687)
|
(29 204)
|
(30 684)
|
(70 994)
|
(33 273)
|
(34 620)
|
(35 449)
|
(81 087)
|
(35 169)
|
(34 639)
|
(34 521)
|
(75 930)
|
(34 612)
|
(34 708)
|
(35 236)
|
(81 895)
|
(35 941)
|
(36 805)
|
(37 485)
|
(88 589)
|
(40 429)
|
|
| Research & Development |
0
|
0
|
0
|
(253)
|
0
|
0
|
0
|
(151)
|
0
|
0
|
0
|
(166)
|
0
|
0
|
0
|
(292)
|
0
|
0
|
0
|
(756)
|
0
|
0
|
0
|
(1 218)
|
0
|
0
|
0
|
(688)
|
0
|
0
|
0
|
(652)
|
0
|
0
|
0
|
(395)
|
0
|
0
|
0
|
(756)
|
0
|
|
| Depreciation & Amortization |
(3 314)
|
(3 447)
|
(3 360)
|
(3 326)
|
(3 309)
|
(3 336)
|
(3 657)
|
(3 924)
|
(4 096)
|
(4 272)
|
(4 389)
|
(4 276)
|
(4 526)
|
(4 745)
|
(5 015)
|
(5 580)
|
(5 813)
|
(6 129)
|
(6 379)
|
(6 680)
|
(7 543)
|
(8 339)
|
(9 209)
|
(9 667)
|
(9 813)
|
(9 953)
|
(10 217)
|
(10 554)
|
(10 795)
|
(11 164)
|
(11 390)
|
(11 265)
|
(11 264)
|
(11 303)
|
(11 526)
|
(12 446)
|
(12 916)
|
(14 110)
|
(15 129)
|
(14 919)
|
(15 993)
|
|
| Other Operating Expenses |
(18 002)
|
(20 823)
|
(24 741)
|
(1 076)
|
(30 154)
|
(30 739)
|
(30 320)
|
(1 153)
|
(30 512)
|
(31 852)
|
(33 057)
|
(1 553)
|
(34 942)
|
(36 912)
|
(37 876)
|
(2 345)
|
(39 463)
|
(39 981)
|
(41 895)
|
(3 386)
|
(45 763)
|
(47 799)
|
(49 605)
|
(3 641)
|
(54 456)
|
(57 678)
|
(59 870)
|
(3 174)
|
(58 884)
|
(56 558)
|
(54 853)
|
(3 170)
|
(57 253)
|
(59 286)
|
(62 140)
|
(5 183)
|
(64 094)
|
(65 678)
|
(65 547)
|
(5 306)
|
(68 434)
|
|
| Operating Income |
21 526
N/A
|
23 383
+9%
|
23 154
-1%
|
22 785
-2%
|
22 998
+1%
|
24 388
+6%
|
26 123
+7%
|
28 008
+7%
|
29 424
+5%
|
30 750
+5%
|
31 403
+2%
|
30 200
-4%
|
29 343
-3%
|
31 005
+6%
|
32 043
+3%
|
32 469
+1%
|
31 448
-3%
|
29 951
-5%
|
30 308
+1%
|
33 035
+9%
|
35 547
+8%
|
36 434
+2%
|
36 781
+1%
|
39 346
+7%
|
39 805
+1%
|
42 452
+7%
|
43 794
+3%
|
44 191
+1%
|
42 059
-5%
|
39 229
-7%
|
35 480
-10%
|
33 003
-7%
|
30 158
-9%
|
25 341
-16%
|
24 151
-5%
|
25 376
+5%
|
26 136
+3%
|
30 606
+17%
|
36 056
+18%
|
43 847
+22%
|
47 119
+7%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(1 298)
|
(999)
|
(1 203)
|
(1 149)
|
(1 726)
|
(1 790)
|
(1 439)
|
(915)
|
(2 380)
|
(1 663)
|
(1 547)
|
287
|
(719)
|
(908)
|
(1 069)
|
(647)
|
(1 655)
|
(2 238)
|
(2 069)
|
(1 946)
|
(1 663)
|
(1 595)
|
(1 937)
|
(1 756)
|
(1 851)
|
(1 467)
|
(913)
|
110
|
(88)
|
13
|
(288)
|
335
|
(636)
|
(1 166)
|
(660)
|
(317)
|
(464)
|
(709)
|
(1 510)
|
419
|
(3 578)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(250)
|
(881)
|
(739)
|
(867)
|
(746)
|
(261)
|
0
|
(6)
|
28 262
|
28 146
|
28 146
|
28 146
|
355
|
(2 440)
|
(1 280)
|
0
|
0
|
(240)
|
(698)
|
(698)
|
(698)
|
(2 542)
|
(1 221)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(157)
|
0
|
0
|
0
|
(50)
|
0
|
0
|
0
|
(63)
|
0
|
0
|
0
|
(164)
|
0
|
0
|
0
|
(195)
|
0
|
0
|
0
|
(370)
|
0
|
0
|
0
|
(1 411)
|
0
|
0
|
0
|
760
|
0
|
0
|
0
|
132
|
0
|
0
|
0
|
235
|
0
|
|
| Total Other Income |
285
|
507
|
830
|
200
|
1 153
|
1 002
|
718
|
400
|
1 903
|
1 864
|
1 868
|
184
|
1 221
|
1 241
|
1 420
|
753
|
1 236
|
1 396
|
1 272
|
900
|
692
|
635
|
721
|
472
|
1 686
|
1 952
|
2 460
|
2 400
|
2 652
|
3 127
|
2 851
|
2 070
|
2 097
|
1 722
|
1 270
|
1 173
|
2 481
|
3 779
|
4 952
|
1 841
|
6 599
|
|
| Pre-Tax Income |
20 513
N/A
|
22 890
+12%
|
22 781
0%
|
21 679
-5%
|
22 427
+3%
|
23 602
+5%
|
25 403
+8%
|
27 443
+8%
|
28 947
+5%
|
30 950
+7%
|
31 723
+2%
|
30 608
-4%
|
29 844
-2%
|
31 338
+5%
|
32 394
+3%
|
32 412
+0%
|
31 029
-4%
|
29 109
-6%
|
29 261
+1%
|
30 914
+6%
|
33 837
+9%
|
34 607
+2%
|
34 819
+1%
|
37 430
+7%
|
39 640
+6%
|
42 931
+8%
|
73 603
+71%
|
73 436
0%
|
72 770
-1%
|
70 516
-3%
|
38 400
-46%
|
33 727
-12%
|
30 340
-10%
|
25 898
-15%
|
24 761
-4%
|
26 125
+6%
|
27 456
+5%
|
32 978
+20%
|
38 802
+18%
|
43 800
+13%
|
48 919
+12%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
(4 854)
|
(5 857)
|
(6 084)
|
(5 966)
|
(6 135)
|
(6 498)
|
(6 677)
|
(7 207)
|
(7 581)
|
(8 054)
|
(8 489)
|
(7 597)
|
(7 499)
|
(7 239)
|
(8 131)
|
(8 183)
|
(7 428)
|
(7 202)
|
(6 181)
|
(7 269)
|
(8 391)
|
(8 881)
|
(9 162)
|
(8 994)
|
(9 729)
|
(11 358)
|
(19 604)
|
(20 098)
|
(19 522)
|
(18 358)
|
(9 678)
|
(7 256)
|
(6 365)
|
(4 786)
|
(4 782)
|
(6 849)
|
(7 686)
|
(9 793)
|
(11 126)
|
(12 110)
|
(13 744)
|
|
| Income from Continuing Operations |
15 659
|
17 032
|
16 695
|
15 713
|
16 289
|
17 102
|
18 725
|
20 236
|
21 366
|
22 897
|
23 235
|
23 012
|
22 346
|
24 100
|
24 264
|
24 229
|
23 603
|
21 907
|
23 080
|
23 645
|
25 446
|
25 727
|
25 658
|
28 437
|
29 912
|
31 574
|
54 000
|
53 338
|
53 248
|
52 158
|
28 722
|
26 471
|
23 975
|
21 112
|
19 979
|
19 277
|
19 770
|
23 186
|
27 675
|
31 690
|
35 175
|
|
| Income to Minority Interest |
39
|
38
|
44
|
45
|
40
|
41
|
17
|
15
|
11
|
1
|
6
|
5
|
6
|
7
|
8
|
3
|
2
|
0
|
(2)
|
2
|
4
|
7
|
8
|
15
|
11
|
14
|
14
|
10
|
11
|
8
|
11
|
10
|
12
|
0
|
(1)
|
(2)
|
8
|
69
|
30
|
40
|
40
|
|
| Net Income (Common) |
15 697
N/A
|
17 069
+9%
|
16 738
-2%
|
15 758
-6%
|
16 329
+4%
|
17 143
+5%
|
18 742
+9%
|
20 251
+8%
|
21 377
+6%
|
22 897
+7%
|
23 240
+1%
|
23 017
-1%
|
22 352
-3%
|
24 108
+8%
|
24 272
+1%
|
24 232
0%
|
23 604
-3%
|
21 906
-7%
|
23 078
+5%
|
23 647
+2%
|
25 448
+8%
|
25 733
+1%
|
25 666
0%
|
28 451
+11%
|
29 925
+5%
|
31 588
+6%
|
54 014
+71%
|
53 348
-1%
|
53 259
0%
|
52 167
-2%
|
28 733
-45%
|
26 482
-8%
|
23 987
-9%
|
21 112
-12%
|
19 978
-5%
|
19 275
-4%
|
19 778
+3%
|
23 255
+18%
|
27 705
+19%
|
31 730
+15%
|
35 214
+11%
|
|
| EPS (Diluted) |
26.92
N/A
|
29.27
+9%
|
28.32
-3%
|
26.99
-5%
|
27.95
+4%
|
29.35
+5%
|
32.03
+9%
|
34.66
+8%
|
36.56
+5%
|
39.34
+8%
|
39.72
+1%
|
39.33
-1%
|
38.14
-3%
|
41.13
+8%
|
41.41
+1%
|
41.36
0%
|
40.29
-3%
|
36.94
-8%
|
39.38
+7%
|
40.36
+2%
|
43.42
+8%
|
43.91
+1%
|
43.8
0%
|
48.56
+11%
|
50.89
+5%
|
53.9
+6%
|
92.17
+71%
|
91.05
-1%
|
90.88
0%
|
89.02
-2%
|
49.03
-45%
|
45.2
-8%
|
40.93
-9%
|
36.03
-12%
|
34.09
-5%
|
32.9
-3%
|
33.75
+3%
|
39.4
+17%
|
47.46
+20%
|
54.15
+14%
|
60.12
+11%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
